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Cardiovascular diseases (CVD) are the leading
cause of death in many developed and developing
countries, such as China, The modifiable risk factors
for CVD are well recognized and appear to be
applicable to different ethnic groups world-wide1 and
include hypertension, diabetes mellitus and
hypercholesterolaemia. The occurrence of each of
these risk factors contributes about 2-4 times to the
risk of myocardial infarction and when they occur in
combination the risk increases geometrically. Apart
from anti-platelet and lipid lowering therapy, are
there specific medical agents that can ameliorate the
risk of CVD?
The renin-angiotension system (RAS) is a
ubiquitous hormonal system present in the circulation
and specific tissues such as the heart, kidneys, blood
vessels and the brain,2 and has been implicated as a
pathogenic mediator of CVD. Blockade of the RAS
using angiotension converting enzyme inhibitors (ACEI)
has been shown to be effective for blood pressure control,
heart failure prevention and treatment, stroke reduction
and renal preservation (especially in the presence of
diabetes mellitus). These seem to be class effects rather
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than agent-specific. Of particular interest is the ability
of ACEI to prevent CVD deaths, myocardial infarction
or stroke as observed in the use of ramipril in the Heart
Outcome Prevention Evaluation (HOPE) trial, 3 in
patients with established coronary artery disease,
peripheral or cerebrovascular disease or diabetes with
end-organ damage. This beneficial impact was
subsequently confirmed in other placebo controlled
randomised studies using perindopril and enalapril.
These observations are thought to be independent
of blood pressure lowering effect by the ACEI. As such,
ACEI should be considered along with antiplatelet and
lipid lowering therapy for preventing adverse CVD
outcomes.
However, the use of ACEIs has its own set of
complications. They include hypotension, renal
dysfunction and especially unproductive cough. In one
study4 in heart failure patients, about 20%, could not
tolerate the ACEI.
On the contrary, type I angiotensin receptor
blockers (ARB) act down-stream to ACEIs. Thus, unlike
the latter, ARBs do not interfere with the action of
alternative vasoactive compounds (such as bradykinin)
and other mediators. So might they be able to offer
similar benefits but be better tolerated? Furthermore,
will there be added benefit in combining ACEI and ARB?
In patients with symptomatic systolic dysfunction,
two ARBs have been shown to be effective. Valsartan
has been compared with captopril in patients with recent
myocardial infarction,5 in which the former at 160 mg/
day was similar to captopril for CVD outcomes.
However, the combination of captopril and 80 mg
valsartan increased the liability to hypotension without
benefit for primary endpoints. However, the use of
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valsartan in patients with symptomatic heart failure with
a background of ACEI reduced hospitalization in heart
failure patients.6 Similarly in patients with symptomatic
heart failure with a recent history of hospitalization,
candesartan at a target dose of 32 mg reduced death and
hospitalization in those intolerant of ACEIs,7 and further
benefits may ensue if given in combination with low
doses of ACEI.8 The use of this possibly beneficial
combination, is nevertheless associated with more
hypotension, and increases creatinine and potassium
levels. The use of other ARBs has either not been studied
or found not to be effective in heart failure patients.
About 30% of those hospitalized with heart failure have
normal or mildly depressed ejection fractions (>40%),
and several randomised studies have been carried out in
this patient population. Candesartan has been shown to
be marginally effective in reducing hospitalization and
death compared to placebo (p=0.051), particularly the
former. 9 On the other hand, the recently reported
i-PRESERVE study using irbesartan 300 mg daily8 in
the elderly with class II or higher grades of heart failure
with normal ejection fraction did not yield improved
CVD outcomes. Reasons for such differences may be
related to the dose of irbesartan used, the high
concomitant use of ACEIs (>1/3), and non-adherence
to ARB therapy. In this regards, an earlier published
study10 of a collaborative effort from the two Hong Kong
universities also reported absence of benefit of ramipril
or irbesartan in this patient group.
Preventing CVD outcomes has been tested using
telmisartan (80 mg) versus ramipril (10 mg) using a
protocol similar to the HOPE study. In the ON TARGET
study,11 telmisartan was shown to be non-inferior to
ramipril in reducing untoward CVD outcomes, but had
a lower incidence of cough (1.1 vs 4.2%, p<0.001) and
angio-oedema (0.1 vs 0.3%, p<0.001). However, the
combination of telmisartan and ramipril increased the
liability to hypotension, syncope and worryingly renal
dysfunction that may require dialysis. Thus such a
combination should not be used in this population.
Similarly, in patients with ACEI intolerance, whilst
telmisartan confers reduction of CVD complication in
this patient population, combining ACEI and ARB have
been reported to increase the liability to hypotension,

2

renal dysfunction and medication withdrawal in heart
failure patients.12

Conclusion
How are we going to synthesize these sets of
conflicting data? While blood pressure lowering effects
of ARBs appear class specific, the same cannot be said
for the treatment of heart failure and prevention of CVD
outcomes in high risk patients. Based on randomised
trials, valsartan and candesartan have been shown to be
effective for symptomatic heart failure, and they
constitute effective alternatives for those who are ACEI
intolerant. Candesartan may confer marginal benefits
in terms of hospitalization when added to ACEIs.
However, the use of ACEI and ARB together should be
balanced against the higher risk of adverse effects,
especially worsening renal function. Amongst all ARBs,
only candesartan has been shown to be effective for
patients with heart failure in patients with relatively
preserved left ventricular function. For preventing
adverse CVD outcomes, ACEIs constitute the preferred
treatment, but telmisartan used alone is a useful
alternative for patients in whom ACEI intolerance is a
potential or established concern.
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